Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder

Name: Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
SKU: 7999
Availability: InStock

$0.00

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder

By John M. Kane, Christoph U. Correll, Grace S. Liang, Joshua Burke, Christopher F. O’Brien

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 47 No. 3 Articles - 2017 Tags: amines, antipsychotic-agents, christoph-u-correll, christopher-f-obrien, double-blind-method, grace-s-liang, john-m-kane, joshua-burke, mood-disorders, psychopharmacology, psychotic-disorders, schizophrenia, tardive-dyskinesia, valbenazine

Description

Description

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder

By John M. Kane, Christoph U. Correll, Grace S. Liang, Joshua Burke, Christopher F. O’Brien

69-76_PB-47-3-2017_Kane

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder

Description

Gender and Schizophrenia

Genetics of Schizophrenia: Recent Advances

Treatment with Olanzapine: Early Predictors of Weight Gain Risk

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder

Description

Related products

Gender and Schizophrenia

Genetics of Schizophrenia: Recent Advances

Ethical Issues in Schizophrenia: Considerations for Treatment and Research

Treatment with Olanzapine: Early Predictors of Weight Gain Risk